Refractory neurogenic detrusor overactivity

International Journal of Clinical Practice

Volumn 60, Issue SUPPL. 151, 2006, Pages 22-26

  Cruz, Francisco ^a   Silva, C ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Bladder augmentation; Botulinum toxin; Neurogenic detrusor overactivity; Refractory detrusor overactivity; Resiniferatoxin; Sacral anterior root stimulation

Indexed keywords

ATROPINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; IMIPRAMINE; LONG ACTING DRUG; MYOBLOCK; NEUROBLOCK; OXYBUTYNIN; PLACEBO; RESINIFERATOXIN; TOLTERODINE; TROSPIUM CHLORIDE;

ABSENCE OF SIDE EFFECTS; ANTIBODY PRODUCTION; AUTONOMIC DYSREFLEXIA; BLADDER DISEASE; BLADDER FUNCTION; BLADDER IRRIGATION; BLADDER SURGERY; CAREGIVER BURDEN; CLINICAL TRIAL; DETRUSOR DYSSYNERGIA; DETRUSOR MUSCLE; DORSAL RHIZOTOMY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INJECTION VOLUME; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG TREATMENT FAILURE; HUMAN; META ANALYSIS; MUSCLE WEAKNESS; NERVE STIMULATION; NONHUMAN; OUTCOME ASSESSMENT; PARALYSIS; PATIENT SATISFACTION; PRIORITY JOURNAL; REINNERVATION; REVIEW; RISK BENEFIT ANALYSIS; SPINAL CORD LESION; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TREATMENT PLANNING; URINE INCONTINENCE; URODYNAMICS; XEROSTOMIA;

EID: 33751332525     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01182.x     Document Type: Review

References (51)

1. O'Leary M, Erickson JR, Smith CP et.al. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med 2003; 26: 159-62.
2. Ethans KD, Nance PW, Bard RJ et.al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004; 27: 214-8.
3. Horstmann M, Schaefer T, Aguilar Y et.al. Neurogenic bladder treatment by doubling the permissible anticholinergic dosage [abstract]. Eur Urol 2005; 4: 165.
4. Schaefer T, Horstmann M, Nagele U et.al. Evaluation of the effectiveness of the combination of two anticholinergic drugs to treat severe cases of neurogenic bladder [abstract]. Eur Urol 2005; 4: 105.
5. Cruz F, Silva C. Botulinum toxin in the management of lower urinary tract dysfunction: Contemporary update. Curr Opin Urol 2004; 14: 329-34.
6. Apostolidis A, Popat R, Yiangou Y et.al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-83.
7. Ghei M, Maraj BH, Miller R et.al. Effects of botulinum toxin B on refractory detrusor overactivity: A randomized, duble-blinded, placebo controlled, crossover trial. J Urol 2005; 174: 1873-7.
8. Odergen T, Hjaltason H, Kaakkola S et.al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998; 64: 6-12.
9. Karsenty G, Boy S, Reitz A et.al. Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI) -a prospective randomized study to compare 30 vs. 10 injection sites [abstract]. Neurourol Urodyn 2005; 24: 547-8.
10. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342: 665.
11. Reitz A, Stohrer M, Kramer G et.al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510-5.
12. Kessler TM, Danuser H, Schumacher M et.al. Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity ? Neurourol Urodyn 2005; 24: 231-6.
13. Popat R, Apostolidis A, Kalsi V et.al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactive to the first intradetrusor injection of botulinum-A toxin. J Urol 2005; 174: 984-9.
14. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47: 653-9.
15. Schurch B, de Séze M, Denys P et.al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6 month study. J Urol 2005; 174: 196-200.
16. Corcos J, Al-Taweel W, Pippi Salle J et.al. The treatment of detrusor hyperreflexia using botulinum A toxin in myelomeningocele patients unresponsive to anticholinergic. Neurourol Urodyn 2002; 21: 39.
17. Schulte-Baukloh H, Michael T, Sturzbecher B, Knispel HH. Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003; 44: 139-43.
18. Riccabona M, Koen M, Schindler M et.al. Botulinum-A toxin injection into the detrusor: A safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004; 171: 845-8.
19. Altaweel W, Corcos J, Robichaud C. Botulinum-A toxin as an alternative treatment to bladder augmentation in children with neurogenic bladder due to myelomenigocele. Eur Urol 2004; 3 (Suppl. 3): 671.
20. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002; 40: 599-600.
21. Del Popolo G, Li Marzi V, Lombardi G. Efficacy, safety and dosage of English botulinum toxin-A in neurogenic detrusor overactivity. Eur Urol 2004; 3 (Suppl. 3): 663.
22. Pistolesi D, Rossi CS, Stampacchia G. Botulinum toxin type B for type A resistant bladder spasticity. J Urol 2004; 171: 802-3.
23. Reitz A, Schurch B. Botulinum toxin type B for management of type A resistant neurogenic detrusor overactivity. J Urol 2004; 171: 804-5.
24. Haferkamp A, Schurch B, Reitz A et.al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 2004; 46: 784-91.
25. Silva C, Rio ME, Cruz F. Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: Long-term results for the treatment of detrusor hyperreflexia. Eur Urol 2000; 38: 444-52.
26. Shin JC, Kim YW, Park CI et.al. Effect of the intravesical resiniferatoxin instillation evaluated by the ice provocative urodynamic study. Spinal Cord 2005; 27: 1-6.
27. Cruz F, Guimarães M, Silva C, Reis M. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 1997; 350: 640-1.
28. Lazzeri M, Beneforti P, Turini D. Urodynamic effects of intravesical resiniferatoxin in humans: Preliminary results in stable and unstable detrusor. J Urol 1997; 158: 2093-6.
29. Lazzeri M, Spinelli M, Beneforti P et.al. Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases. Scand J Urol Nephrol 1998; 32: 331-4.
30. Giannantoni A, Di Stasi SM, Stephen RL et.al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: A prospective randomized study. J Urol 2002; 167: 1710-4.
31. Kuo HC. Effectiveness of intravesical resiniferatoxin in treating detrsuor hyper-reflexia and external sphincter dyssynergia in patients with chronic spinal cord lesions. BJU Int 2003; 92: 597-601.
32. Giannantoni A, Di Stasi SM, Stephen RL et.al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: A prospective randomized study. J Urol 2004; 172: 240-3.
33. de Seze M, Wiart L, de Seze MP et.al. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: A double-blind, randomized, controlled study. J Urol 2004; 171: 251-5.
34. Brady CM, Apostolidis AN, Harper M et.al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 2004; 93: 770-6.
35. Silva C, Silva J, Ribeiro MJ et.al. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenicdetrusor overactivity of spinal origin: Results of a double-blind randomized placebo-controlled trial. Eur Urol 2005; 48: 650-5.
36. Silva C, Avelino A, Souto-Moura C, Cruz F. A light and electron-microscopic histopathological study of human bladder mucosa after intravesical resiniferatoxin application. BJU Int 2001; 88: 355-60.
37. Silva C, Cruz F. Intravesical pharmacological therapy. In: Corcos J, Schick E, eds. Textbook of the Neurogenic Bladder, 1st edn. London: Martin Dunitz, 2004: 507-17.
38. Di Stasi SM, Giannantoni A, Vespasiani G et.al. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergics regimens. J Urol 2001; 165: 491-8.
39. Mundy AR, Stephenson TP. "Clam"ileocystoplasty for the treatment of refractory urge incontinence. Br J Urol 1985; 57: 641-6.
40. Hasan ST, Marshall C, Robson WA, Neal DE. Clinical outcome and quality of life following enteroscystoplasty for idiopathic detrusor instability and neurogenic bladder dysfunction. Br J Urol 1995; 76: 551-7.
41. Herschorn S, Hewitt RJ. Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder. Urology 1998; 52: 672-8.
42. Awad SA, Al-Zahrani HM, Gajewski JB, Bourque-Kehoe AA. Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women. Br J Urol 1998; 81: 569-73.
43. Cartwright PC, Snow BW. Bladder autoaugmentation: Partial detrusor excision to augment the bladder without the use of bowel. J Urol 1989; 142: 1050-3.
44. Swami KS, Feneley RC, Hammonds JC, Abrams P. Detrusor myectomy for detrusor overactivity: A minimum 1-year follow-up. Br J Urol 1998; 81: 68-72.
45. Leng WW, Blalock HJ, Fredriksson WH, English SF, McGuire EJ. Enterocystoplasty or detrusor myectomy? Comparison of indications and outcomes for bladder augmentation. J Urol 1999; 161: 758-63.
46. Brindley GS. Physiological considerations in the use of sacral anterior root stimulators. Neurourol Urodyn 1993; 12: 485-6.
47. Van Kerrebroeck EV, Van der Aa HE, Bosch JL et.al. Sacral rhizotomies and electrical bladder stimulation in spinal cord injury. Part I: clinical and urodynamic analysis. Dutch Study Group on Sacral Anterior Root Stimulation. Eur Urol 1997; 31: 263-71.
48. Kutzenberger J, Domurath B, Sauerwein D. Spastic bladder and spinal cord injury: Seventeen years of experience with sacral deafferentation and implantation of an anterior root stimulator. Artif Organs 2005; 29: 239-41.
49. Kirkham AP, Knight SL, Craggs MD, Casey AT, Shah PJ. Neuromodulation through sacral nerve roots 2 to 4 with a Fenetech-Brindley sacral posterior and anterior root stimulator. Spinal Cord 2002; 40: 272-81.
50. Xiao CG, Du MX, Dai C, Li B, Nitti VW, de Groat WC. An artificial somatic - central nervous system -autonomic reflex pathway for controllable micturition after spinal cord injury: Preliminary results in 15 patients. J Urol 2003; 170: 1237-41.
51. Xiao CG. Reinnervation for neurogenic bladder: Historic review and introduction of a somatic-autonomic reflex pathway procedure for patients with spinal cord injury or spina bifida. Eur Urol 2006; 49: 22-8.